WASHINGTON–(EON: Enhanced Online News)–American Epilepsy Society Annual Meeting, Booth 1101–NeuroPace, Inc., a Silicon Valley-based medical technology company that developed the world’s first and only closed-loop brain-responsive neurostimulation system for epilepsy, today announces 5 poster presentations, including new 8-year prospective clinical trial data presented at the American Epilepsy Society’s (AES) Annual Meeting 2017 in Washington D.C.
RNS System Clinical Trials included 256 adult patients from the feasibility trial, pivotal trial, and long-term treatment trial, representing 1,825 implant years and average follow up of 8.1 years. Key findings from these prospective trials demonstrate sustained, long-term patient benefits including:
- A median seizure reduction of 73% at year 8
- A 90% seizure reduction or better in 30% of patients in the most recent three months
- Seizure-free periods lasting 1 year or greater experienced by 18% of patients
“In addition to compelling therapeutic benefits, the RNS System is the only device that provides information about a patient’s brain activity over months and years,” notes Martha Morrell, MD, Chief Medical Officer at NeuroPace. “With over 1.5 million stored brain recordings, the unprecedented data from the RNS System is helping us advance science. It is fueling research on seizure biomarkers, seizure forecasting, effects on memory, and possible synergies between specific antiepileptic medication and neuromodulation. We are optimistic that the clinical insights gained from this large body of data will continue to help clinicians improve their patients’ outcomes.”
For a full list of posters, visit www.neuropace.com/aes-2017. Selected poster highlights include:
- 2:120: Interictal spike rates are negatively correlated with verbal memory in patients with mesial temporal lobe epilepsy.
- Prior studies have shown that RNS System patients with mesial temporal lobe (MTL) epilepsy experienced statistically significant improvements in verbal memory, but these results were not correlated with clinical seizure counts.
- New analyses show that a reduction in interictal epileptiform spikes in the left mesial temporal lobe is associated with significant improvements in verbal memory. The findings suggest that epileptiform spikes may interfere with one aspect of memory.
- 2.122: Differential clinical responses to different antiepileptic medications in patients being treated with responsive neurostimulation.
- Clobazam and levetiracetam significantly improved the clinical response already achieved with the RNS System. In contrast, the clinical response was not further improved with lacosamide or pregabalin.
- This raises the possibility that certain AEDs could act synergistically with neurostimulation and that potential biomarkers can be used to objectively assess whether a patient may have a favorable clinical response to a new antiepileptic medication.
- 2.142: Deep Learning for seizure classification and potential seizure biomarker discovery.
- Using machine learning and deep learning techniques, interictal spike rate (for patients with mesial temporal lobe seizures) and high gamma power (for neocortical onset patients) were shown to be the most significant features for differentiating high and low responders, with >90% classification accuracy.
- Insights obtained from analyzing successful classifiers may lead to potential seizure biomarker discovery that can predict patient clinical outcomes and personalize treatment plans.
About the NeuroPace RNS® System
The RNS System is the world’s first and only closed-loop brain-responsive neurostimulation system designed to prevent epileptic seizures at their source. The RNS System treats seizures by continuously monitoring brain waves, detecting unusual activity, and automatically responding with imperceptible electrical pulses before seizures occur. Physicians can program the detection and stimulation parameters of the implanted RNS neurostimulator to personalize therapy for each individual. The RNS® System is an adjunctive therapy for adults with refractory, partial onset seizures with no more than 2 epileptogenic foci.
About NeuroPace
NeuroPace is an innovative medical device company dedicated to improving quality of life for individuals with medically refractory partial onset seizures. In addition to treating epilepsy, responsive neurostimulation holds the promise of treating other disabling neurological, psychiatric, and chronic disorders that negatively impact quality of life for millions of patients throughout the world.
Contacts
MSL
Hillary Marder, 781-684-0770
NeuroPace@mslgroup.com
